CA2784120A1 - Compositions et procedes d'administration de medicaments par voie orale - Google Patents

Compositions et procedes d'administration de medicaments par voie orale Download PDF

Info

Publication number
CA2784120A1
CA2784120A1 CA2784120A CA2784120A CA2784120A1 CA 2784120 A1 CA2784120 A1 CA 2784120A1 CA 2784120 A CA2784120 A CA 2784120A CA 2784120 A CA2784120 A CA 2784120A CA 2784120 A1 CA2784120 A1 CA 2784120A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
layer
exenatide
tablets
bioadhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2784120A
Other languages
English (en)
Inventor
William W. Lee
Feng Lu
Yin Min
Liuying Shao
Hao SHE
Zhou Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOD Pharmaceuticals Inc
Original Assignee
NOD Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN200910201248.3A external-priority patent/CN102100912B/zh
Priority claimed from CN201010227045.4A external-priority patent/CN102335431B/zh
Application filed by NOD Pharmaceuticals Inc filed Critical NOD Pharmaceuticals Inc
Publication of CA2784120A1 publication Critical patent/CA2784120A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
CA2784120A 2009-12-16 2010-12-16 Compositions et procedes d'administration de medicaments par voie orale Abandoned CA2784120A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28714609P 2009-12-16 2009-12-16
CN200910201248.3 2009-12-16
US61/287,146 2009-12-16
CN200910201248.3A CN102100912B (zh) 2009-12-16 2009-12-16 一种给药组合物及其制备和使用方法
CN201010227045.4 2010-07-14
CN201010227045.4A CN102335431B (zh) 2010-07-14 2010-07-14 一种给药组合物及其制备和使用方法
US36591610P 2010-07-20 2010-07-20
US61/365,916 2010-07-20
PCT/US2010/060809 WO2011084618A2 (fr) 2009-12-16 2010-12-16 Compositions et procédés d'administration de médicaments par voie orale

Publications (1)

Publication Number Publication Date
CA2784120A1 true CA2784120A1 (fr) 2011-07-14

Family

ID=44306059

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2784120A Abandoned CA2784120A1 (fr) 2009-12-16 2010-12-16 Compositions et procedes d'administration de medicaments par voie orale

Country Status (5)

Country Link
EP (1) EP2512454A2 (fr)
JP (1) JP2013514976A (fr)
AU (1) AU2010339907A1 (fr)
CA (1) CA2784120A1 (fr)
WO (1) WO2011084618A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
EP3326620B1 (fr) 2010-12-16 2020-03-04 Novo Nordisk A/S Compositions solides comportant un agoniste glp-1 et du sel de n-(8-(2-hydroxybenzoyl)amino)caprylate
CA2832811A1 (fr) 2011-04-12 2012-10-18 Novo Nordisk A/S Derives de glp-1 a double acylation
US8846620B2 (en) * 2011-07-19 2014-09-30 Baxter International Inc. Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
EP4324475A1 (fr) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions de peptides glp-1 et leur préparation
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
US20160193154A1 (en) * 2013-07-24 2016-07-07 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating
KR101768446B1 (ko) * 2014-03-21 2017-08-17 애니젠 주식회사 신규한 엑세나타이드 유사체 및 그의 용도
CN107072955B (zh) 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3250225A1 (fr) * 2015-01-29 2017-12-06 Novo Nordisk A/S Composition pharmaceutique pour l'administration d'insuline par voie orale comprenant un noyau de comprimé et un enrobage d'alcool polyvinylique
US20180263915A1 (en) * 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
EP3250191B1 (fr) * 2015-01-29 2024-01-17 Novo Nordisk A/S Comprimés contenant un agoniste de glp-1 et revêtement gastro-résistant
EP3280447B1 (fr) * 2015-04-08 2019-02-27 Torrent Pharmaceuticals Limited Formulations pharmaceutiques
AU2016257813B2 (en) * 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
CN104998251A (zh) * 2015-07-08 2015-10-28 哈尔滨吉象隆生物技术有限公司 用于口服肠溶制剂制备的具有促肠吸收作用的利拉鲁肽盐
CN105079794A (zh) * 2015-07-18 2015-11-25 哈尔滨吉象隆生物技术有限公司 一种可用于口服的利拉鲁肽与磺脲类复方制剂
CN105079793A (zh) * 2015-07-18 2015-11-25 哈尔滨吉象隆生物技术有限公司 一种可用于口服的利拉鲁肽与盐酸二甲双胍复方制剂
RU2617049C1 (ru) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство на основе никлозамида
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
EP0200508B1 (fr) 1985-04-27 1991-10-02 Nitto Denko Corporation Emplâtres adhésifs et préparations pharmaceutiques pour la cavité buccale
NL8701143A (nl) 1986-05-27 1987-12-16 Sandoz Ag Farmaceutische preparaten.
US6156731A (en) 1989-05-10 2000-12-05 G. D. Searle & Co. Polypeptide composition for oral administration
JPH0813748B2 (ja) * 1990-04-23 1996-02-14 帝國製薬株式会社 大腸崩壊性ポリペプチド系経口製剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
JPH064531B2 (ja) * 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5318781A (en) 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5424289A (en) 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
AU689250B2 (en) * 1994-04-22 1998-03-26 Astellas Pharma Inc. Colon-specific drug release system
ES2180658T3 (es) 1994-11-17 2003-02-16 Toray Industries Preparado para absorcion percutanea.
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5817624A (en) 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
CA2184316A1 (fr) 1995-09-12 1997-03-13 Wei-Chi Liao Systeme d'administration buccale pour agents therapeutiques
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
JP2001503062A (ja) 1996-10-30 2001-03-06 セラテック・インコーポレーテッド 透過促進剤としての乳酸の脂肪酸エステルの塩
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CA2294988C (fr) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions et procedes d'apport d'oligonucleotides par le tube digestif
US6423334B1 (en) 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
JPH11246439A (ja) 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
IL143356A0 (en) 1998-11-27 2002-04-21 Takada Kanji An oral formulation for gastrointestinal drug delivery
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
ES2301477T3 (es) 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
CA2531136A1 (fr) * 2003-07-04 2005-01-13 Nycomed Danmark Aps Compositions pharmaceutiques contenant une hormone parathyroide (pth) administrees par voie orale
EP1720520B1 (fr) 2004-02-13 2010-06-09 Nod Pharmaceuticals, Inc. Particules contenant un noyau des nanoparticules de phosphate de calcium, un biomolécule et l'acide biliaire, le procédé de production, l'emploi thérapeutique
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090087484A1 (en) 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20090111736A1 (en) 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
JP2011519867A (ja) 2008-05-01 2011-07-14 ノッド ファーマシューティカルズ， インコーポレイテッド 治療用リン酸カルシウム粒子、ならびにその作製および使用方法

Also Published As

Publication number Publication date
WO2011084618A2 (fr) 2011-07-14
EP2512454A2 (fr) 2012-10-24
WO2011084618A3 (fr) 2012-01-19
AU2010339907A1 (en) 2012-07-05
JP2013514976A (ja) 2013-05-02

Similar Documents

Publication Publication Date Title
US20110142889A1 (en) Compositions and methods for oral drug delivery
CA2784120A1 (fr) Compositions et procedes d'administration de medicaments par voie orale
US20180098934A1 (en) Mucoadhesive devices for delivery of active agents
ES2301477T3 (es) Forma de dosificacion oral solida que contiene un potenciador.
EP0932396B1 (fr) Forme posologique pharmaceutique comportant plusieurs enrobages polymeres enteriques, destinee a agir dans le colon
US20230073256A1 (en) Oral delivery of active drug substances
US8053429B2 (en) Solid oral dosage form containing an enhancer
CA2642479C (fr) Systeme de gastro-retention pour de livrer des macromolecules
EP2526950A1 (fr) Forme pharmaceutique solide par voie orale contenant un activateur
CN102552919B (zh) 一种给药组合物及其制备和使用方法
CN102100912B (zh) 一种给药组合物及其制备和使用方法
WO2009125432A2 (fr) Systèmes d'administration de médicament expansible alimentés par gaz
CN102335431B (zh) 一种给药组合物及其制备和使用方法
WO2015026552A2 (fr) Dispositifs mucoadhésifs permettant l'administration d'agents actifs
CN110974943A (zh) 一种口服胰岛素药物制剂及其制备方法
US20190192442A1 (en) Room temperature stable oral calcitonin formulation
WO2023131885A1 (fr) Dispositif d'administration de médicament auto-expansible à avaler et ses utilisations
CN110809464A (zh) 粘膜附着性口服制剂

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141216